With the improvement of malignancy diagnosis, more and more ovarian malignant germ cell tumors are detected at an early stage and conservative surgery is performed, and postoperative adjuvant chemotherapy significantly improves the survival rate of MOGCT, and conservative treatment of patients with advanced stages has also been confirmed. We believe that the recurrence and survival rates of MOGCT patients are not affected by fertility preserving surgery or radical or staged surgery. Mangili et al [[ii]] summarized the prognosis of 123 patients with MOGCT, 87 in stage I, 3 in stage II, 29 in stage III, and 4 in stage IV. Lopez Chuken et al [[iii]] reviewed the data of 39 patients with MOGCTs, and all patients with stage I and II fertility preserving surgery survived tumor-free with a median survival of 62 months. This suggests that patients with early stage MOGCTs have an excellent prognosis and that fertility preservation therapy does not decrease the cure rate. Young-Tak et al [[iv]] summarized 101 patients who underwent fertility preserving surgery for MOGCTs, 68 in stage I, 15 in stage II, 17 in stage III, and 1 in stage IV, with a median follow-up of 58 months, 13 patients relapsed after surgery, 3 died of the disease, and 6 patients became pregnant at term and produced 5 normal healthy infants. Chan et al[v]] analyzed a large sample of MOGCT patients in the SEER database and concluded that conservative surgery did not affect survival. Lee et al[[vi]] reported 196 MOGCT patients with FIGO stage I 128, stage II 27, stage III 39, stage IV 2, and 134 patients with preserved fertility, with a 5-year overall survival rate of 96.7%. 20 patients had 22 pregnancy outcomes, including 17 normal full-term deliveries and 5 miscarriages. It is believed that most ovarian malignant germ cell tumors have good survival outcomes after conservative surgery and platinum-based chemotherapy treatment.